Virtu Financial LLC Takes Position in Genmab A/S Sponsored ADR $GMAB

Virtu Financial LLC acquired a new position in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 22,620 shares of the company’s stock, valued at approximately $697,000.

Several other institutional investors also recently modified their holdings of GMAB. CIBC Private Wealth Group LLC raised its stake in Genmab A/S by 291.9% in the fourth quarter. CIBC Private Wealth Group LLC now owns 827 shares of the company’s stock valued at $25,000 after purchasing an additional 616 shares in the last quarter. Osaic Holdings Inc. raised its position in shares of Genmab A/S by 37.8% during the 2nd quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock valued at $33,000 after buying an additional 440 shares in the last quarter. NewEdge Advisors LLC lifted its holdings in shares of Genmab A/S by 1,229.0% during the 3rd quarter. NewEdge Advisors LLC now owns 1,236 shares of the company’s stock worth $38,000 after acquiring an additional 1,143 shares during the last quarter. Brown Brothers Harriman & Co. lifted its holdings in shares of Genmab A/S by 143.4% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 1,324 shares of the company’s stock worth $41,000 after acquiring an additional 780 shares during the last quarter. Finally, Founders Capital Management grew its position in Genmab A/S by 40.0% in the fourth quarter. Founders Capital Management now owns 1,400 shares of the company’s stock worth $43,000 after acquiring an additional 400 shares in the last quarter. 7.07% of the stock is currently owned by institutional investors.

Genmab A/S Price Performance

GMAB opened at $25.61 on Tuesday. The company has a debt-to-equity ratio of 0.87, a current ratio of 2.18 and a quick ratio of 2.17. The stock’s 50 day simple moving average is $26.44 and its 200 day simple moving average is $28.95. The firm has a market cap of $15.97 billion, a price-to-earnings ratio of 19.40, a PEG ratio of 1.50 and a beta of 0.85. Genmab A/S Sponsored ADR has a 1 year low of $20.23 and a 1 year high of $35.43.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on GMAB shares. Truist Financial started coverage on Genmab A/S in a research note on Wednesday, May 27th. They issued a “buy” rating and a $40.00 target price on the stock. BNP Paribas Exane upgraded Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Wednesday, April 22nd. Wolfe Research began coverage on Genmab A/S in a research report on Friday, March 27th. They set an “outperform” rating and a $32.00 price objective on the stock. Wells Fargo & Company began coverage on Genmab A/S in a report on Monday, March 2nd. They set an “overweight” rating and a $40.00 price objective on the stock. Finally, HC Wainwright dropped their target price on Genmab A/S from $40.00 to $38.00 and set a “buy” rating for the company in a research report on Thursday, April 30th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Genmab A/S has an average rating of “Moderate Buy” and an average price target of $37.93.

Genmab A/S Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.